# High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis

> **NCT00002810** · PHASE2 · COMPLETED · sponsor: **Temple University**

## Conditions studied

- Multiple Myeloma and Plasma Cell Neoplasm

## Interventions

- **BIOLOGICAL:** filgrastim
- **DRUG:** melphalan
- **PROCEDURE:** bone marrow ablation with stem cell support
- **PROCEDURE:** peripheral blood stem cell transplantation

## Key facts

- **NCT ID:** NCT00002810
- **Lead sponsor:** Temple University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-05
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** — (—)
- **Last updated:** 2010-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002810, "High-Dose Melphalan Followed by Peripheral Stem Cell Transplant in Treating Patients With Amyloidosis". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00002810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*